OKUR vs AUPH vs JPM

For growth investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger pick with 20. 4% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 7. 6x trailing P/E (16. 5x forward), making it the more compelling value choice. Analysts rate Aurinia Pharmaceuticals Inc. (AUPH) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Aurinia Pharmaceuticals Inc.

(AUPH) is the cheapest at 7. 6x versus JPMorgan Chase & Co. at 16. 0x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -96. 4% for OnKure Therapeutics, Inc. (OKUR). Over 10 years, the gap is even starker: AUPH returned +499. 2% versus OKUR's -97. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus OnKure Therapeutics, Inc. 's 1. 34β — meaning OKUR is approximately 42% more volatile than JPM relative to the S&P 500. On balance sheet safety, OnKure Therapeutics, Inc. (OKUR) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aurinia Pharmaceuticals Inc.

(AUPH) is pulling ahead at 20. 4% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Aurinia Pharmaceuticals Inc. grew EPS 51. 7% year-over-year, compared to -11. 4% for OnKure Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurinia Pharmaceuticals Inc.

(AUPH) is the more profitable company, earning 101. 5% net margin versus 0. 0% for OnKure Therapeutics, Inc. — meaning it keeps 101. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37. 1% versus 0. 0% for OKUR. At the gross margin level — before operating expenses — AUPH leads at 88. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, JPMorgan Chase & Co.

(JPM) trades at 14. 4x forward P/E versus 16. 5x for Aurinia Pharmaceuticals Inc. — 2. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JPM: 5. 9% to $339. 75.

In this comparison, JPM (1.

9% yield) pays a dividend. OKUR, AUPH do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Both have compounded well over 10 years (JPM: +465. 8%, OKUR: -97. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OKUR (Healthcare) and AUPH (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OKUR is a small-cap quality compounder stock; AUPH is a small-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while OKUR, AUPH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.